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ABSTRACT
Background
One of the complications of esophageal varices ligation is deep ulcer. Sucralphate has been shown to
prevent and heal post ligation esophageal ulcer.
Materials and method
All patients with liver cirrhosis and portal hypertension undergoing esophageal varices ligation in the
year 2000/2001 were included in this study. Using “double-blind random sampling”, patients were divided
into 2 groups, those receiving sucralphate and those receiving placebo for 2 weeks. Endoscopy of the upper
gastrointestinal tract was conducted regularly on the 7th, 10th, and 14th day to evaluate the diameter of the
esophageal ulcer based on the diameter of forceps biopsy. The data were evaluated using analysis of vari-
ance (ANOVA) or Kruskal Wallis.
Results
Statistically, there was no significant difference in the characteristics of group A patients receiving
sucralphate and group B patients receiving placebo. Only 17 patients from group A and 20 from group B
were allowed to participate in this study. On the 10th day, the average diameter of the esophageal ulcer in the
sucralphate group was significantly smaller than that from the placebo group. (4.74 + 2.02 mm vs 5.42 +
2.22 mm; p=0.04). On the 14th day, the average diameter of esophageal ulcer in the sucralphate group was
also significantly less than that of the placebo group (0.88 + 1.58 vs 2.99 + 2.04 mm; p < 0.01).
Conclusion
Sucralphate is able to accelerate the healing of post esophageal varices ligation ulcer.
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INTRODUCTION
One of the complications of ligation of esophageal
varices is deep esophageal ulcer.1,2,3,4,5,6 The presence
of esophageal ulcer creates symptoms of chest pain,
chest discomfort, fever, bleeding, etc. Sucralphate is a
cyto-protective agent that is able to facilitate healing of
damaged gastrointestinal mucosal epithelial cells, includ-
ing esophageal ulcer. Several studies using sucralphate
to prevent and heal post esophageal varices ligation
esophageal ulcer have demonstrated satisfactory re-
sults.7,8,9,10,11
This study attempts to study the effect of sucralphate
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in healing post esophageal varices ligation esophageal 
ulcer compared to placebo. 
 
MATERIALS AND METHODS 
All patients with liver cirrhosis and portal hyperten- 
sion undergoing endoscopic esophageal varices ligation  
at Cipto Mangunkusumo General Hospital from mid 2000  
to mid 2001 were included in the study. Using double- 
blind random sampling, patients were divided into 2  
groups, the first one (group A) given 4 x 1 gram of fluid  
sucralphate, and the second (group B) were given 4 x 1  
cc of fluid placebo for 2 weeks. Endoscopy of the upper  
gastrointestinal tract (GIT) was repeated on the 7th, 10th,  
and 14th day. The ulcer that is formed is measured based  
on forceps biopsy width (5 mm when open). All side  
effects related to the administration of sucralphate or  
placebo is regularly noted. Data were statistically evalu- 
ated using analysis of variance (ANOVA) or Kruskal - 
wallis. 
 
RESULTS 
From the study, we matched the characteristics of  
patients from group A and B. No significant difference  
in age, sex, race/ethnic background was found (see table 
1). 
The youngest patient was 26 years old, and the old- 
est 62 years old, with a mean of 48.5 +  9.612 years.  
 Out of the 25 patients receiving sucralphate, 17 were  
able to undergo endoscopic evaluation, while the remain- 
 
Table 1. Characteristics of Subjects Receiving Sucralphate and Placebo 
Characteristics Sucralphate Placebo P value 
(n=25) (n=28) 
Age: 3 2 0,49 
20-29 7 5 
30-39 5 9 
40-49 9 8 
50-59 1 4 
60-69 
Sex: male 16 17 0,97 
Female 9 11 
Ethnic group: 
Batak 5 3 0,92 
Bengkulu 1 2 
Betawi 3 4 
Java 13 14 
Manado 2 3 
Pontianak 1 2 
ing 8 did not come for control visit, and thus were ex- 
cluded from the study. 
Out of the 28 patients receiving placebo, 20 patients 
were available for endoscopic evaluation, while 8 pa- 
tients also did not come for control visit, and thus were 
excluded from the study. 
DISCUSSION 
Treatment of esophageal varices, both ligation of 
esophageal varices or sclerotherapy, have been known 
to cause deep esophageal ulcer.1-6 Medications such as 
sucralphate are needed to accelerate ulcer healing and 
to prevent further complications such as bleeding or in- 
fection/septicemia. 
This is a double blind random sampling study on the  
effect of sucralphate administration in post-esophageal  
ulcer ligation ulcer. Liver cirrhosis patients with post- 
esophageal varices ligation were divided into two groups,  
those receiving sucralphate and placebo. The charac- 
teristics of the two groups were matched to ensure  
equivalence in age, sex, and race/ethnic background.  
 On the 7th day, the average diameter of ulcer in the  
first group of patients (group A) receiving fluid sucralphate  
was significantly less than that of the second group  
(group B) receiving fluid placebo. The average diam- 
eter of ulcer in the sucralphate group was 6.18 + 2.83,  
which was smaller than the average diameter of ulcer  
from the placebo group (7.39 + 5.06). However, the dif- 
ference was not statistically significant (p > 0.05).  
 On the 10th day, average diameter of ulcer in the  
sucralphate group (4.74 + 2.02) was significantly smaller  
than the average diameter of ulcer from the placebo group  
(5.42 + 2.22) (p < 0.05). 
On the 14th day, average diameter of ulcer in the 
sucralphate group (0.88 + 1.58) was significantly smaller 
than the average diameter of ulcer from the placebo group 
(2.99 + 2.04) (p < 0.01). 
The average diameter of esophageal ulcer in the  
sucralphate group was smaller compared to the placebo  
group, which was in accordance to literature that stated  
that patients receiving sucralphate had accelerated heal- 
ing of esophageal ulcer.7-11 Patients receiving sucralphate  
or placebo did not demonstrate drug side-effects as in  
other studies. This study found several drop-outs from  
both the sucralphate and the placebo group due to igno- 
rance, non-compliance, and aggravated conditions. 
CONCLUSION 
Sucralphate is capable of accelerating healing of post- 
esophageal varices ligation esophageal ulcer.  
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Table 2. Mean diameter of Post-Esophageal Varices Ligation Esophageal Ulcer 
on the 7th, 10th and 14th day. 
Mean diameter of 
esophageal ulcer 
(mm) 
7th day 
(mm) 
10th day 
(mm) 
14th day 
(mm) 
Sucralphate (n=17) 6.18 + 2.83 4.74 + 2.02 0.88 + 1.58 
Placebo (n=20) 7.39 + 5.06 5.42 + 2.22 2.99 + 2.04 
P value 0.07 0.04 0.004 
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